Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT07285330
Recruiting Observational

Dietitian-Nutritionist vs. Day Hospital in the Metabolic Control of Patients With Type 2 Diabetes

NCT07285330 · tracked via the Priya Life Science Spain tracker
Sponsor
Consorci Sanitari de l'Alt Penedès i Garraf
Phase
Observational
Started
2025-06-30
Last updated
2025-12-16

Condition(s) studied

Diabetes (DM)

Investigational drug(s) / intervention(s)

Day Care HospitalNutritionist

Day Care Hospital: Clinical follow-up under the joint care of a nurse and an endocrinologist at Day Care Hospital

Nutritionist: Clinical follow-up with a dietitian-nutritionist and an endocrinologist at ambulatory care unit

Study summary

The present study aims to compare the effects on glycated hemoglobin (HbA1c) at 3 months of two care models in patients with type 2 diabetes referred due to poor glycemic control: a day hospital endocrinology care model versus a care model centered on follow-up by a dietitian-nutritionist.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with a diagnosis of type 2 diabetes (T2DM) referred to endocrinology due to poor metabolic control. * Patients on insulin therapy Exclusion Criteria: * Referred from primary care for other reasons such as hypoglycemia. * Patients with other types of diabetes mellitus or with uncertainty in diagnostic classification. * Patients on rapid-acting insulin bolus therapy. * Patients with acute decompensation of diabetes. * Patients receiving corticosteroid treatment. * Dependent individuals for activities of daily living (ADL) with a Barthel index score below 60 or with cognitive impairment. * Language barrier.

Primary outcome measure(s)

  • Glycate hemoglobin — three months after completion of the intervention
    Glycated hemoglobin (HbA1c) levels three months after completion of the intervention

Trial sites (1)

FacilityCityRegionStatus
Hospital de Vilafranca Vilafranca del Penedès Barcelona Recruiting

More Consorci Sanitari de l'Alt Penedès i Garraf trials in Spain

Acetic Acid 2% Solution for Skin Ulcers Recruiting
Neuropsychological Assessment Of The Oldest-Old Population.(NEUROPSIC-GR) Recruiting
Levels of Diagnostic and Therapeutic Intervention in Hospitalized Patients Starting soon
High-risk Antithrombotic Drugs at Discharge and Consultation for Hemorrhagic or Thromboembolic Events in the Emergency Department Starting soon
Prevalence of Amyloidosis in Trauma Patients Recruiting

Other trials for the same condition

Nut Consumption and Prevention of Non-communicable Diseases: A Global Individual Participant Data Meta-analysis Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07285330 on ClinicalTrials.gov ↗ ← All trials in Spain